source
- Arrowhead’s siRNA shows strong tau reduction in early human study, outpacing other BBB platformsArrowhead Pharmaceuticals reported that its investigational siRNA candidate ARO-MAPT produced notable reductions in cerebrospinal fluid tau in a Phase 1/2a trial of healthy volunteers. Doses of 2.…
- Iambic Therapeutics raises $150 million in IPO, begins Nasdaq trading under ticker IAMIambic Therapeutics, an AI-driven drug discovery startup, completed an initial public offering that raised $150 million. The company sold about 9.4 million shares at $16 each and will start tradin…BioPharma Dive · 5d agoDealPositive